AbCellera Announces Multi-Target Research Collaboration with Pfizer
January 05 2017 - 9:00AM
AbCellera Biologics, Inc. announced today a new therapeutic
antibody discovery collaboration with Pfizer Inc. (NYSE:PFE).
AbCellera will apply its proprietary monoclonal antibody (mAb)
screening platform to attempt to discover function-modulating
antibodies against undisclosed membrane protein targets.
Carl Hansen, founding CEO of AbCellera, commented: “We are
increasingly recognized as a leader in high-performance antibody
discovery. Our platform allows us to screen natural immune
repertoires with unparalleled depth to unlock the most challenging
discovery programs. This partnership reinforces our commitment to
offer leading-edge antibody discovery capabilities and to create
value for companies by providing access to our platform. We welcome
the opportunity to work closely with the innovative team at Pfizer
and look forward to building a lasting relationship.”
“We are pleased to work with the team at AbCellera using their
innovative antibody discovery platform,” said Will Somers, Vice
President of Biomedicines Design, Pfizer. “We hope this platform
can aid in our research as we look to bring novel medicines to
patients, seeking to discover modulators of a transmembrane protein
in a therapeutically important target class.”
Under the terms of the agreement, AbCellera will receive an
upfront payment and research support, and will be eligible to
receive up to approximately $90 million in contingent milestone
payments, as well as tiered mid-to-low single digit royalty
payments based on Pfizer’s development and commercialization of
antibodies that may be generated under this collaboration. Further
terms of the agreement are not disclosed.
About AbCellera Biologics, Inc.
AbCellera is a privately held biotechnology company that
provides enabling technologies for the discovery and development of
monoclonal antibody (mAb) therapies directly from natural immune
cells.
AbCellera’s lead technology is a proprietary single cell
antibody discovery platform that provides pharmaceutical and
biotechnology partners with the ability to rapidly identify mAb
therapeutic candidates from the natural immune repertoires of any
species, including humans.
Contact
Kevin Heyries
Telephone: 604.827.4151
Email: media@abcellera.com
Web: www.abcellera.com
Pfizer (NYSE:PFE)
Historical Stock Chart
From Apr 2024 to May 2024
Pfizer (NYSE:PFE)
Historical Stock Chart
From May 2023 to May 2024